IP Library Granted Patent US 7,645,790
Granted Patent B2
US 7,645,790 · App. 10/586,727 · Granted Jan 12, 2010

Hydroisoindoline tachykinin receptor antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,645,790
App. No.
10/586,727
Granted
Jan 12, 2010
Kind
B2
Abstract

The present invention is directed to certain hydroisoindoline compounds of formula I which are useful as neurokinin-1 (NK-1) receptor antagonists, and inhibitors of tachykinin and in particular substance P. The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including emesis, urinary incontinence, depression, and anxiety.

Claims (19)

1. A method for treating alcohol dependence in a patient in need thereof,

comprising administering to the patient a therapeutically effective amount of a compound of formula I:

wherein:

R 1 is selected from the group consisting of:

(1) hydrogen,

(2) C 1-6 alkyl, which is unsubstituted or substituted with halogen, hydroxyl or phenyl,

(3) cyclopentenone, which is unsubstituted or substituted with hydroxyl or methyl,

(4) —(CO)—C 1-6 alkyl,

(5) —(CO)—NH 2 ,

(6) —(CO)—NHC 1-6 alkyl, and

(7) —(CO)—N(C 1-6 alkyl)(C 1-6 alkyl);

X is independently selected from the group consisting of:

(1) hydrogen,

(2) fluorine, and

(3) methyl;

and pharmaceutically acceptable salts thereof and individual enantiomers and diastereomers thereof.

2. The method according to claim 1 wherein the compound of Formula I is selected from the group consisting of:

and pharmaceutically acceptable salts thereof.

3. A method for treating alcohol dependence in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound which is

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057531/0986 →
PATENT SECURITY AGREEMENT Recorded Mar 9, 2020
From: MENLO THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 052130/0980 →
CHANGE OF NAME Recorded Aug 29, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028866/0511 →
MERGER Recorded Aug 27, 2012
From: MERCK SHARP & DOHME CORP.
To: SCHERING CORPORATION
Reel/Frame 028850/0515 →
CHANGE OF NAME Recorded Nov 24, 2009
From: MERCK & CO., INC
To: MERCK SHARP & DOHME CORP.
Reel/Frame 023563/0437 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2009
From: BUNDA, JAIME L.; DEVITA, ROBERT J.; MILLS, SANDER G.; JIANG, JINLONG
To: MERCK & CO., INC.
Reel/Frame 022311/0057 →